Vimarsana
Biggest News Aggregation in the World

Page 4 - Early Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Early Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Early Access Program Today - Breaking & Trending Today

Biometric Tech Arrives on SimpliSafe Platform - Vimarsana News

Biometric Tech Arrives on SimpliSafe Platform

SimpliSafe is taking an innovative approach to home security, blending AI and facial recognition with human oversight.

GenSight: financial visibility assured until the end of April -April 05, 2024 at 06:43 am EDT - Vimarsana News

GenSight: financial visibility assured until the end of April -April 05, 2024 at 06:43 am EDT

GenSight Biologics is trading lower on the Paris Bourse on Friday, with analysts noting the company's continuing lack of cash visibility.At March 31, the company's net cash position stood at 2.2...

AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript - Vimarsana News

AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript

Operator: Hello. And welcome to the AIM ImmunoTech Fiscal Year 2023 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Vimarsana News

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Year marked by growing body of promising data demonstrating Ampligen’s potential to address multiple high-value indications Company to host conference call and webcast today, April 2nd at 8:30...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research - Vimarsana News

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 -- AIM ImmunoTech Inc.   today announced the...